Table 2.

Dose modification for tisotumab for ocular adverse events (AE). Modified from https://www.tivdakhcp.com/eye-care/. Starting dose 2 mg/kg (max 200 mg), 1st dose reduction 1.3 mg/kg (max 130 mg), 2nd dose reduction 0.9 mg/kg (max 90 mg).

Severity	Occurrence	Dose Modification
Keratitis
Superficial punctate (SPK)	Any	Monitor
Confluent superficial	First	Hold dose until SPK or resolved, then dose reduce 1 level
	Second	Permanently discontinue
Ulcerative or perforation	Any	Permanently discontinue
Conjunctival ulceration	First	Hold dose until complete conjunctival re-epithelialization, then dose reduce 1 level
	Second	Permanently discontinue
Conjunctival or corneal scarring or symblepharon	Any	Permanently discontinue
Conjunctivitis and other AE
Grade 1	Any	Monitor
2	First	Hold dose until Grade ≤ 1, then resume same dose
	Second	Hold dose until Grade ≤ 1, then dose reduce 1 level
	Third	Permanently discontinue
3 or 4	Any	Permanently discontinue